hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06271304, orgStudyIdInfo id: BLUES, briefTitle: Stabilizing Mood and Sleep With Blue Blocking Eyewear in Bipolar Disorder, acronym: BLUES, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2026-03-01, completionDateStruct date: 2026-06-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Mental Health Services in the Capital Region, Denmark, class: OTHER, descriptionModule briefSummary: The study investigates whether add-on treatment with eyewear that blocks the short wavelengths of visible light (\<500nm) reduces manic symptoms and improves sleep in patients receiving outpatient treatment as usual for bipolar disorder.When in a hypomanic or manic phase, participants will be randomized to receive add-on treatment with either blue blocking or low filtration eyewear from 18 PM to 8 AM daily for 7 days.After this initial intervention phase, the eyewear is used daily for 3 months in either antimanic dose (14 hours) or maintenance dose (2 hours before bedtime)., conditionsModule conditions: Bipolar Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Outcome assessors will be blinded to the treatment assignment. At the beginning of each assessment, participants will be instructed not to describe or discuss their glasses with the assessor. Because the two types of glasses are of different color (clear (LF) and orange (BB)), we cannot guarantee a full blinding of the participants. Participants will be informed that we are studying the effects of two different types of light filters without more detail so they will not be provided with certain knowledge of which condition is expected to yield the largest effect. We will assess the integrity of the blind by asking participants whether they think they received glasses with high or low filtration lenses at the end of the study. Participants will be discouraged from actively seeking information about sleep glasses during the study, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Participants are instructed not to discuss the appearance of their designated eyewear with their care providers or the investigator or outcome assessor. Participants are not informed of the exact filtration level of their eyewear., whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Blue blocking eyewear, interventions name: Low filtration eyewear, outcomesModule primaryOutcomes measure: Manic symptoms, secondaryOutcomes measure: Mood instability, secondaryOutcomes measure: Objective sleep quality, secondaryOutcomes measure: Objective sleep quality, secondaryOutcomes measure: Subjective sleep quality, secondaryOutcomes measure: Subjective sleep quality, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06271291, orgStudyIdInfo id: 23-000161, secondaryIdInfos id: NCI-2024-00504, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 23-000161, type: OTHER, domain: Mayo Clinic in Rochester, secondaryIdInfos id: P30CA015083, type: NIH, link: https://reporter.nih.gov/quickSearch/P30CA015083, secondaryIdInfos id: U01CA210138, type: NIH, link: https://reporter.nih.gov/quickSearch/U01CA210138, secondaryIdInfos id: U24CA274496, type: NIH, link: https://reporter.nih.gov/quickSearch/U24CA274496, briefTitle: Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2029-05-01, completionDateStruct date: 2029-05-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, collaborators name: National Cancer Institute (NCI), descriptionModule briefSummary: This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured., conditionsModule conditions: Pancreatic Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 15000, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Develop a biobank of biospecimens and data of subjects without pancreatic cancer who are at high risk for pancreatic cancer, primaryOutcomes measure: Follow subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: City of Hope, city: Duarte, state: California, zip: 91010, country: United States, contacts name: Ajay Goel, Ph.D., role: CONTACT, phone: 626-256-4673, phoneExt: 85200, contacts name: Ajay Goel, Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.13945, lon: -117.97729, locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: Shounak Majumder, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, locations facility: University of Pittsburgh, city: Pittsburgh, state: Pennsylvania, zip: 15232, country: United States, contacts name: Randall Brand, M.D., role: CONTACT, phone: 412-864-7516, geoPoint lat: 40.44062, lon: -79.99589, hasResults: False
protocolSection identificationModule nctId: NCT06271265, orgStudyIdInfo id: 402-C-125, briefTitle: Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Pacira Pharmaceuticals, Inc, class: INDUSTRY, descriptionModule briefSummary: This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA)., conditionsModule conditions: Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: EXPAREL, interventions name: bupivacaine, outcomesModule primaryOutcomes measure: The following model-predicted PK endpoint will be determined:, primaryOutcomes measure: The following model-predicted PK endpoint will be determined:, primaryOutcomes measure: The following model-predicted PK endpoint will be determined:, primaryOutcomes measure: The following model-predicted PK endpoint will be determined:, primaryOutcomes measure: The following model-predicted PK endpoint will be determined:, primaryOutcomes measure: The following model-predicted PK endpoint will be determined:, secondaryOutcomes measure: Vitals change from Baseline:, secondaryOutcomes measure: Vitals change from Baseline:, secondaryOutcomes measure: Vitals change from Baseline:, secondaryOutcomes measure: Vitals change from Baseline:, secondaryOutcomes measure: Vitals change from Baseline:, secondaryOutcomes measure: Incidence of treatment-emergent adverse events (TEAEs), secondaryOutcomes measure: Incidence of adverse events of special interest (AESIs), secondaryOutcomes measure: Incidence of serious adverse events (SAEs), eligibilityModule sex: ALL, minimumAge: 0 Years, maximumAge: 6 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06271252, orgStudyIdInfo id: OriCAR-017 US-P1, briefTitle: A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2025-12-01, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: OriCell Therapeutics Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The is a first clinical study for Oricell Therapeutics Inc. in the United States to evaluate the safety, PK, PD and preliminary efficacy of our anti-GPRC5D cell product (OriCAR-017) in subjects with relapsed/refractory multiple myeloma.RIGEL Study, conditionsModule conditions: Neoplasms, Plasma Cell, conditions: Neoplasms by Histologic Type, conditions: Neoplasms, conditions: Hemostatic Disorders, conditions: Vascular Diseases, conditions: Cardiovascular Diseases, conditions: Paraproteinemias, conditions: Blood Protein Disorders, conditions: Hematologic Diseases, conditions: Hemorrhagic Disorders, conditions: Lymphoproliferative Disorders, conditions: Immunoproliferative Disorders, conditions: Immune System Diseases, conditions: Multiple Myeloma, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 81, type: ESTIMATED, armsInterventionsModule interventions name: OriCAR-017, outcomesModule primaryOutcomes measure: Maximum tolerated dose (MTD) of OriCAR-017 US-P1, primaryOutcomes measure: Dose-limiting toxicity (DLT), secondaryOutcomes measure: Evaluate PK parameters of OriCAR-017 in subjects with relapsed/refractory MM, secondaryOutcomes measure: Evaluate PD parameters of OriCAR-017 in subjects with relapsed/refractory MM, secondaryOutcomes measure: Assessment of Duration of Response (DOR) of treatment in patients with RR/MM, secondaryOutcomes measure: Progress-Free Survival (PFS) of treatment in patients with RR/MM, secondaryOutcomes measure: Assessment of Overall Survival (OS) of treatment in patients with RR/MM, secondaryOutcomes measure: Assessment of MRD negative Rate, secondaryOutcomes measure: Assessment of Overall Response Rate (ORR), secondaryOutcomes measure: Assessment of Disease Control Rate (DCR), secondaryOutcomes measure: Assessment of Clinical Benefit Rate (CBR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Northside Hospital, city: Atlanta, state: Georgia, zip: 30342, country: United States, contacts name: Melhem Solh, role: CONTACT, email: msolh@bmtga.com, contacts name: Caitlin Guzowski, role: CONTACT, email: caitlin.guzowski@northside.com, geoPoint lat: 33.749, lon: -84.38798, hasResults: False
protocolSection identificationModule nctId: NCT06271187, orgStudyIdInfo id: A-ER-110-507, briefTitle: Dynamic-orthosis Programs for Stroke Hand Function, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-22, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: National Cheng-Kung University Hospital, class: OTHER, descriptionModule briefSummary: This study aims to investigate the training benefits of modular 3D printed dynamic orthoses on upper limb function in stroke survivors., conditionsModule conditions: Stroke, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Dynamic-orthosis, interventions name: Traditional stroke occupational therapy training, outcomesModule primaryOutcomes measure: Fugl-Meyer Assessment- Upper Extremity, primaryOutcomes measure: Box and Block Test, primaryOutcomes measure: Motor Activity Log, secondaryOutcomes measure: Modified Ashworth scale, secondaryOutcomes measure: Upper limb joint range of motion, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: National Cheng Kung University, status: RECRUITING, city: Tainan, zip: 701, country: Taiwan, contacts name: JER-HAO CHANG, PH.D., role: CONTACT, phone: 886-6-2353535, phoneExt: 5912, email: jerhao@ncku.edu.tw, geoPoint lat: 22.99083, lon: 120.21333, hasResults: False
protocolSection identificationModule nctId: NCT06271174, orgStudyIdInfo id: RC23_0009, briefTitle: Avoid With Locoregional Analgesia Persistant Postoperative Pain In Children, acronym: AWA3PASIC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2026-05, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Nantes University Hospital, class: OTHER, collaborators name: Fondation Apicil, descriptionModule briefSummary: Persistent postoperative pain is a substantial pain (scores 4-10 using a 0-10 numeric scale) that develops 3 months after surgery.Persistent postoperative pain can be a problem even in ambulatory surgery. Loco-regional analgesia could prevent the occurrence of this pathology but contradictory results are found in ancient studies.This study is the first randomized controlled study in children about loco-regional analgesia and persistent postoperative pain in traumatologic orthopedic surgery.One interventional arm will receive a locoregional analgesia after general anesthesia and before incision. The other arm will only receive systemic analgesia during general anesthesia.The incidence of persistent postoperative pain at 3, 6 and 12 months will be compared in these two groups.The goal is to show the decrease of the incidence of the persistent postoperative pain in the group "locoregional analgesia"., conditionsModule conditions: Persistent Postoperative Pain, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 208, type: ESTIMATED, armsInterventionsModule interventions name: Carbocaine, interventions name: Profofol and/or Suxaméthonium and/or Sévoflurane, outcomesModule primaryOutcomes measure: Persistent Postoperative Pain, secondaryOutcomes measure: Screening of neuropathic pain if persistent postoperative pain - 3 months, secondaryOutcomes measure: Screening of neuropathic pain if persistent postoperative pain - 6 months, secondaryOutcomes measure: Screening of neuropathic pain if persistent postoperative pain - 12 months, secondaryOutcomes measure: 1st EN score in immediate post-operative ICU before morphine titration, secondaryOutcomes measure: Persistent postoperative pain at 6 months., secondaryOutcomes measure: Persistent postoperative pain at 12 months., secondaryOutcomes measure: Postoperative nausea and vomiting, secondaryOutcomes measure: Time in Post Interventional Care Unit, secondaryOutcomes measure: Opioïd dose received - Per-operative, secondaryOutcomes measure: Opioïd dose received - in Post Interventional Care Unit, secondaryOutcomes measure: Opioïd dose received, secondaryOutcomes measure: Intravenous Morphine dose received in Post Interventional Care Unit, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 183 Months, stdAges: CHILD, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06271161, orgStudyIdInfo id: F002, briefTitle: The Effect of Pharyngeal Cooling Applications on Postoperative Throat Pain and Nausea Vomiting, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-11-01, completionDateStruct date: 2024-01-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Selcuk University, class: OTHER, descriptionModule briefSummary: The goal of this observational study is to to evaluate the effects of a throat pack soaked with saline at +4 ºC on postoperative throat pain (POTP) and postoperative nausea and vomiting (PONV) in dental surgical procedures performed under general anesthesia. The main questions it aims to answer are: 1. How long can we keep the pharyngeal mucosa cold using tampons and cold wash solutions? 2. Does cooling the pharyngeal mucosa reduce the incidence of postoperative sore throat and nausea and vomiting?, conditionsModule conditions: Postoperative Pain, conditions: Postoperative Nausea and Vomiting, conditions: Throat, Sore, conditions: Anesthesia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 84, type: ACTUAL, outcomesModule primaryOutcomes measure: The incidence of postoperative sore throat and noise vomiting was investigated in dental surgery involving the application of cooling to the pharyngeal area, particularly when a throat pack was used., secondaryOutcomes measure: Intraoperative change in nasopharyngeal temperature from baseline (ºC ), intraoperative opioid usage (mcg), postoperative analgesic usage (mg),antiemetic usage(mg) and any adverse events due to throat pack were recorded., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Funda Arun, city: Selçuklu, state: Konya, zip: 42000, country: Turkey, geoPoint lat: 37.8842, lon: 32.49222, hasResults: False
protocolSection identificationModule nctId: NCT06271148, orgStudyIdInfo id: Mutah University, secondaryIdInfos id: Myah REC/133/2023, type: REGISTRY, domain: Mutah university school of medicine, briefTitle: Career and Lifestyle Among Female Surgeons in Jordan, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-03, primaryCompletionDateStruct date: 2023-12-17, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Mohammad Abu-Jeyyab, class: OTHER, descriptionModule briefSummary: A study conducted to evaluate the female surgeons in Jordan from different lifestyle, conditionsModule conditions: Surgery, conditions: Lifestyle, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 224, type: ACTUAL, armsInterventionsModule interventions name: Interview, outcomesModule primaryOutcomes measure: Career and Lifestyle Among Female Surgeons in Jordan, primaryOutcomes measure: Working Hours, primaryOutcomes measure: Sex Bias, primaryOutcomes measure: inadequate mentorship, primaryOutcomes measure: having 30 days of leave, primaryOutcomes measure: salary, eligibilityModule sex: FEMALE, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mutah University, city: Al-Karak, zip: 61710, country: Jordan, geoPoint lat: 31.16368, lon: 35.76204, hasResults: False
protocolSection identificationModule nctId: NCT06271135, orgStudyIdInfo id: LU20170508, briefTitle: Assessing the Quality of Life of Patients With Rosacea, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-05-08, primaryCompletionDateStruct date: 2018-11-30, completionDateStruct date: 2018-11-30, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Medical University of Bialystok, class: OTHER, collaborators name: University of Lomza, descriptionModule briefSummary: The study population consisted of 160 patients (123 women and 37 men) with rosacea, who agreed to participate in this study. Patients were qualified for the study among people visiting the cosmetic studio in Choroszcz in the period from June 2017 to November 2018, based on the diagnosis of a dermatologist and cosmetologist. The cosmetic intervention was performed using CAPILLARY REPAIR SERUM (30ml). Study participants completed self-reported questionnaire and standardized questionnaires., conditionsModule conditions: Rosacea, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 160, type: ACTUAL, armsInterventionsModule interventions name: CAPILLARY REPAIR SERUM 30ml, outcomesModule primaryOutcomes measure: Elements influenced on quality of life of participants with rosacea, secondaryOutcomes measure: Self-reported questionnaire, secondaryOutcomes measure: Dietary Questionnaire, secondaryOutcomes measure: The Physical Activity Questionnaire, secondaryOutcomes measure: DLQI (Dermatology Life Quality Index), secondaryOutcomes measure: SWLS (Satisfaction With Life Scale), secondaryOutcomes measure: BDI (Beck Depression Inventory), eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Medical University of Bialystok, city: Białystok, zip: 15-089, country: Poland, geoPoint lat: 53.13333, lon: 23.16433, hasResults: False
protocolSection identificationModule nctId: NCT06271109, orgStudyIdInfo id: Soh-Med-24-01-04MD, briefTitle: Short Term Surgical Outcomes of Anatomical Versus Non Anatomical Laparoscopic Liver Resection for Liver Tumors, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2021-12-01, primaryCompletionDateStruct date: 2025-06-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-02-21, lastUpdatePostDateStruct date: 2024-02-21, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: aimed to discuss the short term surgical outcomes of Anatomical versus Non anatomical laparoscopic Liver resection for Liver tumors., conditionsModule conditions: Liver Neoplasms, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Anatomical laparoscopic liver resection for liver neoplasms, interventions name: Non-Anatomical laparoscopic liver resection for liver neoplasms, outcomesModule primaryOutcomes measure: complete resection of the neoplasm, secondaryOutcomes measure: residual liver tissue, secondaryOutcomes measure: recurrence rate, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sohag University, city: Sohag, country: Egypt, geoPoint lat: 26.55695, lon: 31.69478, hasResults: False